Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis

The epidermal growth factor receptor (EGFR) family belongs to type I receptor tyrosine kinases. Overexpression or mutation of EGFR/ErbB1 gene has been detected in a large number of human solid tumours. According to some previous report, this gene is not expressed in hematological malignancies. Howev...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2012-06, Vol.30 (2), p.89-97
Main Authors: Sun, Jun-Zhong, Lu, Ying, Xu, Yin, Liu, Fang, Li, Fu-Quan, Wang, Quan-Li, Wu, Chu-Tse, Hu, Xian-Wen, Duan, Hai-Feng
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antibody-Dependent Cell Cytotoxicity
Apoptosis
Cell Line, Tumor
Cell Movement
clinical prognosis
epidermal growth factor receptor
Female
hematological malignancies
Humans
Leukemia, Myeloid, Acute - metabolism
Leukemia, Myeloid, Acute - mortality
Leukemia, Myeloid, Acute - pathology
Male
Middle Aged
Prognosis
Proportional Hazards Models
Receptor, Epidermal Growth Factor - analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The epidermal growth factor receptor (EGFR) family belongs to type I receptor tyrosine kinases. Overexpression or mutation of EGFR/ErbB1 gene has been detected in a large number of human solid tumours. According to some previous report, this gene is not expressed in hematological malignancies. However, two recent clinical case reports showed that erlotinib caused complete remission of acute myeloid leukaemia (AML)‐M1 in patients who had both AML‐M1 and non‐small‐cell lung cancer. These results are supported by preclinical studies in which EGFR tyrosine kinase inhibitors have anti‐proliferative effects on AML. These findings prompted us to determine whether EGFR is expressed in human AML, through a large‐scale screening of both leukaemic cell lines and clinical samples. Our results show that EGFR is expressed by about 33% of human AML (containing M1 to M7 subtypes) and by some human leukaemia cell lines (K562, MEG‐01, CEM and SKO‐007). Its expression is not limited to certain AML types but has been detected in many leukaemic cells. In addition, EGFR expression was intimately associated with the poor clinical outcomes. Finally, we find that only EGFR‐positive leukaemic cells respond to antibody‐dependent cellular cytotoxicity of cetuximab, the monoclonal antibodies against EGFR. Copyright © 2011 John Wiley & Sons, Ltd.
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.1002